Tradestie Institutional Equity Comparison Engine

CDNA vs IMDX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CDNA Overall Edge

CDNA Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CareDx, Inc. (CDNA) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CDNA trades at 46.0x Forward P/E with 1.6% operating margin (+39.3% YoY revenue) versus IMDX at N/M Forward P/E and -1883.2% operating margin (+115.0% YoY). In options structure, CDNA sits in CONSOLIDATION (34th %ile IV; Dealer Gamma Walls on Pro) against IMDX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CDNA
CDNA 46.0x vs IMDX N/M Fwd P/E
Growth & Margin Winner CDNA
Op Margin 1.6% vs -1883.2% ยท YoY +39.3% vs +115.0%
Momentum & Technical Winner CDNA
1Y +356.4% vs -73.8% ยท 52W Pos 75% vs 3%
Options & Structure Winner CDNA
CONSOLIDATION (34th %ile IV) vs BREAKDOWN (12th %ile IV)
CDNA NASDAQ
CareDx, Inc.
Services-Medical Laboratories
$71.92
-3.39% 1D
Market Cap $3.9B
1M Return +1.67%
1Y Return +356.35%
Forward P/E 46.0x
Unified AI Score
32.0 / 100 SELL
Tech 31.0 Fund 48.0 Flow 70.0 Mom 36.0
IMDX NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap $52.1M
1M Return -45.03%
1Y Return -73.78%
Forward P/E N/M
Unified AI Score
45.5 / 100 HOLD
Tech 50.0 Fund 40.0 Flow 58.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CDNA +356.35% IMDX -73.78% Spread: +430.13 pp (CDNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CDNA Revenue IMDX Revenue CDNA Op. Margin IMDX Op. Margin Margin Edge
FY2018 $80M N/A -20.3% N/A CDNA
FY2019 $130M N/A -19.3% N/A CDNA
FY2020 $190M $0M -11.7% -2443.3% CDNA
FY2021 $300M $0M -10.0% -2444.3% CDNA
FY2022 $320M $0M -24.0% -1878.6% CDNA
FY2023 $280M $0M -72.5% -1672.4% CDNA
FY2024 $330M $0M 12.2% -3245.1% CDNA
FY2025 $380M $0M -8.1% -1260.8% CDNA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CDNA (7) vs IMDX (3)
Institutional Metric CDNA IMDX Criterion Row Winner
Market Capitalization Scale $3.9B $52.1M Larger Scale CDNA
Trailing P/E Ratio Valuation 31.5x N/M Lower Multiple CDNA
Forward P/E Ratio Valuation 46.0x N/M Lower Multiple CDNA
Revenue Growth (YoY) Growth +39.3% +115.0% Higher Growth IMDX
Operating Margin (TTM) Profitability 1.6% -1883.2% Higher Margin CDNA
Net Profit Margin Profitability 25.9% 0.0% Higher Margin CDNA
Return on Equity (ROE) Capital Efficiency 33.0% -23603.1% Higher ROE CDNA
52-Week Range Position Momentum 75% ($15โ€“$91) 3% ($2โ€“$8) Stronger Trend CDNA
Beta / 30D Volatility Risk Regime 1.22ฮฒ ยท 97% Vol 2.91ฮฒ ยท 76% Vol Lower Realized Risk IMDX
Unified Institutional Score Composite Signal 32.0 / 100 (SELL) 45.5 / 100 (HOLD) Higher Composite IMDX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CDNA vs IMDX Buy Guide
CDNA CONSOLIDATION
33d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 34th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CDNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IMDX BREAKDOWN
117d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live IMDX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CDNA nor IMDX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.